Xenacare Holdings Inc.(fka XCHO)

[stervc]

With Ortho-McNeil, Johnson & Johnson and XCHO…

Ortho-McNeil works with and is a division of Johnson & Johnson (J&J) and Janssen Pharmaceuticals, Inc. …

http://www.ortho-mcneil.com/ortho-mcneil/051807_press_release.html
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is part of Johnson & Johnson, the world's most broadly-based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide. …

http://www.janssen.com/janssen/
Janssen Pharmaceuticals, Inc.:
http://www.ortho-mcneil.com/ortho-mcneil/
http://www.pricara.com/pricara/pages/index.jsp;jsessionid=KFTSkrhCJGWQwC6nLkYMftbjX17gG9DTQwzTlt3kYtdT6lvHYJy3!-270944810

***************************************************************************************************

Ortho-McNeil has Ultram (tramadol hydrochloride) as one of their products:
http://www.ortho-mcneil.com/ortho-mcneil/products_list.html

ULTRAM® ER (tramadol HCI) Extended-Release Tablets
www.ultram-er.com


Here is the full US Prescribing Information for Ultram (tramadol hydrochloride):
http://www.ortho-mcneil.com/ortho-mcneil/shared/pi/ultramer.pdf#zoom=100

***************************************************************************************************

This further confirms these posts below about the American Society of Clinical Oncology (ASCO) where the bottom line was…
http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=16&abstractID=1762
… Conclusions: CKLQ (Cobroxin) might be an effective analgesic for treatment of chronic moderate to severe cancer pain as an alternative to tramadol hydrochloride (Ultram).
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=40520224
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=40517406

Now with this being the ”clinically proven” case that Cobroxin would logically be selected as the medicine of choice to relieve chronic moderate to severe cancer pain (and other pains) over Ultram (tramadol hydrochloride), consider what XCHO could logically conceive to be a part of making in Revenues considering since they have now received the exclusive U.S. license to market and distribute this FDA approved homeopathic treatment for chronic pain given the data indicated below:

http://www.bio-medicine.org/biology-technology-1/Circ-Pharma-Limited-Enters-Into-Development-Agreement-for-Chrono-Tramadol-With-Elan-Corporation-Plc-11895-1/

…The tramadol market in the US and Europe was worth about $1.1 billion in 2008. …

I like XCHO’s changes for growth the more I research what is happening here with this Cobroxin. I think all should familiarize themselves with the PR below which should set the stage for the next PR to come given now that the company has returned from the EMCR Conference:

http://finance.yahoo.com/news/XenaCare-Holdings-Receives-bw-1183789224.html?x=0&.v=5
XenaCare Holdings Receives Exclusive License to Market and Distribute an FDA Approved Over the Counter Treatment for Chronic Pain

v/r
Sterling